Sam Niles is an associate in the Corporate Department of Latham & Watkins.

Mr. Niles is a generalist corporate lawyer who advises entrepreneurs, management teams, financial institutions and other corporate clients on a wide variety of matters involving corporate and securities law, including:

  • Registered public offerings, including initial public offerings (IPOs) and follow-on equity and debt offerings
  • Alternative financing transactions, including Private Investments in Public Equity (PIPEs), At-the-Market offerings (ATMs) and special purpose acquisition company (SPAC) IPO and de-SPAC transactions
  • Emerging company matters through all stages of growth, including early-stage formation and strategy, venture capital equity and debt financings, employment matters, commercial and strategic transactions and corporate governance matters

Mr. Niles' recent experience includes advising:

Public Offerings

  • The underwriters in Aerovate Therapeutics’ US$140 million IPO of common stock
  • Aziyo Biologics in its US$50 million IPO of Class A and Class B common stock
  • Lyra Therapeutics in its US$60 million IPO of common stock
  • Homology Medicines in its:
    • US$166 million initial public offering of common stock
    • Multiple follow-on public offerings of common stock
  • The underwriters in connection with Rubius Therapeutics':
    • US$275 million IPO of common stock
    • US$200 follow-on public offering of common stock
  • The underwriters in connection with Kaleido Biosciences'
    • US$75 million IPO of common stock
    • Subsequent follow-on public offerings of common stock
  • The underwriters in resTORbio’s US$98 million IPO of common stock
  • Ra Pharma in its US$150 million follow-on public offering of common stock
  • ContraFect in its US$52 million public offering of common stock and warrants to purchase common stock and concurrent private placement of common stock and warrants to purchase common stock
  • The underwriter in Collegium Pharmaceutical’s US$125 million registered public offering of senior convertible notes
  • The underwriters in Blueprint Medicines’ US$345 million follow-on public offering of common stock
  • The underwriter in Akebia Therapeutics' US$89 million follow-on public offering of common stock
  • The underwriters in Clearside Biomedical's US$85 million follow-on public offering of common stock

Alternative Financing Transactions

  • Everest Consolidator in its US$172 million SPAC IPO of units
  • Aziyo Biologics in its US$14 million PIPE financing
  • Lyra Therapeutics in its US$100 million PIPE financing
  • Rafael Holdings in its US$104 million PIPE financing
  • The sales agent in Neptune Wellness’ US$50 million ATM program of common stock under the US-Canadian multijurisdictional disclosure system
  • Affiliates of Ally Bridge Group in multiple venture capital, PIPE, and other alternative investments
  • Mallinckrodt on certain securities matters relating to its chapter 11 bankruptcy proceedings

Emerging Company Matters

  • Indigo Agriculture in its US$535 million Series F financing and on prior investment rounds
  • Dewpoint Therapeutics in its US$150 million Series C financing, and on prior investment rounds and formation and general corporate matters
  • Kojin Therapeutics in its US$60 million Series A financing and on formation and general corporate matters
  • KSQ Therapeutics in its US$80 million Series C financing and on in prior investment rounds and on general corporate matters
  • Biothea Pharma in its Series A financing
  • CIBO Technologies in its US$30 million Series C financing and on prior investment rounds and general corporate matters
  • Jnana Therapeutics in its US$50 million Series B financing and on general corporate matters
  • Ring Therapeutics in its US$117 million Series B financing and on general corporate matters
  • Cellarity in its US$123 million Series B financing and on general corporate matters
  • Atea Pharmaceuticals in its US$215 million Series D financing
  • Centrexion Therapeutics in its US$67 million Series D financing and on general corporate matters
  • Various other early-stage venture-backed start-up companies, in financing, securities, employment, intellectual property, and general corporate governance matters

Bar Qualification

  • Massachusetts
  • New York

Education

  • JD, Columbia Law School, 2015
    James Kent Scholar
  • BA, Columbia University, 2010

Languages Spoken

  • English